Explore

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics, a California-based biotech company, has released preliminary clinical data for its gene-edited sickle cell disease (SCD) therapy, nula-cel. The data, to be presented at the American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three patients. These patients have also demonstrated restored expression of adult hemoglobin (HbA) and have become transfusion-independent, experiencing no pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). Unlike FDA-approved Casgevy, which increases fetal hemoglobin (HbF), Kamau's nula-cel therapy directly replaces the SCD mutation using homology-directed repair (HDR). The company reports that sickle hemoglobin (HbS) levels fell below 20% of total hemoglobin in two patients who reached the 6-month post-infusion mark. The Phase I/II RESTORE trial is currently enrolling 15 participants.

UCLA Advances CRISPR Gene-Editing Therapy for Sickle Cell Disease Towards Clinical Trials

UCLA Advances CRISPR Gene-Editing Therapy for Sickle Cell Disease Towards Clinical Trials

A UCLA-led research team has successfully advanced an experimental CRISPR gene-editing approach for sickle cell disease, developing a blood stem cell therapy suitable for clinical trials. This therapy utilizes CRISPR-Cas9 gene editing to directly correct the single-point mutation responsible for sickle cell disease within a patient's own blood-forming stem cells. Unlike existing FDA-approved gene therapies that either add a modified gene or boost fetal hemoglobin production, this new method employs a nonviral DNA template to guide the precise correction of the mutation. Preclinical studies demonstrated a reproducible manufacturing process capable of processing hundreds of millions of cells, meeting quality requirements for purity and viability. Edited stem cells differentiated into red blood cells in vitro produced significantly less sickle hemoglobin, and studies in mice showed stable corrected gene copies over 16 weeks without notable toxicity.

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

The U.S. Food and Drug Administration (FDA) has approved a new oral pellet formulation of Orladeyo (berotralstat) for adults and adolescents aged 12 and older who suffer from hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by sudden, unpredictable episodes of swelling in various parts of the body, including the skin, gut, and potentially life-threatening swelling in the airway. Orladeyo functions as a once-daily prophylactic oral therapy, working to block plasma kallikrein, which is responsible for the swelling in HAE. The original capsule formulation of Orladeyo received FDA approval in 2020. The new pellet formulation was initially approved for children aged 2 to 11 last December and is now extended to adolescents and adults, particularly benefiting those who experience difficulty swallowing capsules or prefer this alternative administration method. This development represents a strategic move in pharmaceutical lifecycle management, aiming to enhance patient convenience and adhe...

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics has announced positive interim six-month data from its Phase I/II EMERALD trial, which is evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy (RMT). The trial focuses on patients suffering from end-stage liver disease (ESLD). The data indicates a signal of efficacy in clinical outcomes such as death, liver transplant, and hepatic decompensation. RTX001 was well tolerated by patients, with no serious adverse reactions related to infusion and no severe adverse events attributed to the treatment. Furthermore, prospectively defined biomarkers showed reductions in inflammation and fibrogenesis markers, aligning with the predicted mechanism of regenerative macrophages. The company plans to discuss the program with the FDA and advance RTX001 towards a planned U.S. pivotal trial. These findings will be presented at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) published an interim Enforcement Discretion Policy regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Signed by HHS Secretary Robert F. Kennedy Jr., this policy outlines conditions under which HHS will not take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians who compound drug products using six specific peptide bulk drug substances. This interim measure is in effect while the official list of bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) is being developed through rulemaking. The policy aims to discourage the use of 'research use only' peptides from foreign manufacturers, offering a more controlled alternative for U.S. patients. Notably, this policy was issued by the HHS Office of the Secretary, rather than the FDA, despite FDA scientific reviewers having previously recommended against listing these pep...

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance detailing its patient-centered approach to assessing clinical trial applications that rely on non-clinical safety data generated outside the Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance of Data framework. This guidance, issued on November 4, 2026, aims to support a more risk-proportionate approach to clinical research, thereby advancing the development of new treatments and increasing opportunities for UK patients to participate in trials. While data generated within the OECD framework remains the expected standard, the MHRA will now consider non-OECD data in individual applications, particularly when supported by evidence and the circumstances of the intended patient population.

FDA and HHS Submit Interim Policy for Compounding Peptides Amid Increased Enforcement

FDA and HHS Submit Interim Policy for Compounding Peptides Amid Increased Enforcement

The U.S. Department of Health and Human Services (HHS) and the FDA submitted an 'Interim Access Policy for Compounding Using Certain Peptides' to the Office of Management and Budget for regulatory review on October 14, 2026. This move comes as the FDA has intensified enforcement actions against research-use-only peptide sellers and high-volume compounders since August 2026. While senior HHS leadership has publicly supported broader access to peptides, the FDA has not yet added any peptide to its 503A Bulks List, which would allow pharmacies to compound them. The advisory committee's July 2026 recommendations to add six peptides to this list are advisory only, and formal rulemaking has not begun. Any near-term access is likely to come through temporary FDA enforcement discretion, which would not constitute product approval and could be withdrawn.

Cordyceps Mushroom Under Study for Energy Metabolism and Immune Function, Emphasizing Bioactive Compounds

Cordyceps Mushroom Under Study for Energy Metabolism and Immune Function, Emphasizing Bioactive Compounds

Cordyceps Mushroom Under Study for Energy Metabolism and Immune Function, Emphasizing Bioactive Compounds

FDA Clears Magnetic e-Resonance Therapy for PTSD, Showing High Remission Rates

FDA Clears Magnetic e-Resonance Therapy for PTSD, Showing High Remission Rates

A new non-medication treatment for Post-Traumatic Stress Disorder (PTSD), Magnetic e-Resonance Therapy (MeRT), has received FDA clearance. Developed by California-based Wave Neuroscience in collaboration with researchers at the Texas A&M Health Institute of Biosciences and Technology, MeRT reported a 68 percent remission rate in clinical trials. This figure significantly surpasses the remission rates of currently approved PTSD medications, which typically reach around 10.9 percent. The treatment involves mapping a patient's brain activity using an electroencephalogram (EEG) and then employing an AI-assisted algorithm to create a personalized magnetic stimulation plan. This plan is delivered via transcranial magnetic stimulation (TMS), a technique already FDA-cleared for treatment-resistant depression. Unlike standard TMS, MeRT customizes the stimulation based on individual brain activity. Participants in the trials underwent five sessions per week for five to six weeks, with improvements observed to persis...